Celyad Oncology Announces February 2022 Conference Schedule

Rhea-AI Summary

Celyad Oncology announced its participation in the 11th Annual SVB Leerink Global Healthcare Conference from February 14 to 18, 2022, with a presentation scheduled for February 18 at 8 a.m. ET by CEO Filippo Petti. The company focuses on developing chimeric antigen receptor T cell (CAR T) therapies for cancer, including both allogeneic and autologous treatments for hematological malignancies and solid tumors. Celyad has received funding from the Walloon Region of Belgium to support its CAR T programs.

Positive

• Participation in a significant healthcare conference can enhance visibility and investor interest.
• Focus on CAR T therapies positions the company in a high-demand sector of cancer treatment.
• Secured funding from the Walloon Region facilitates advancement of CAR T programs.

Negative

• No specific clinical data or achievements are highlighted in the PR, limiting insights for investors.

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:

Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company plans to participate virtually in the following conference in February 2022:

Virtual 11th Annual SVB Leerink Global Healthcare Conference 2022
Dates: Monday, February 14 to Friday, February 18, 2022
Presentation: February 18, 8 a.m. ET / 2 p.m. CET
Presenter: Filippo Petti, CEO

Webcast: A live and archived webcast of the presentation will be available in the Events section of the Celyad Oncology website.

About Celyad Oncology SA

Celyad Oncology SA is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com.

Forward-looking statements

This release may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the clinical activity and safety and tolerability of CYAD-211 and expectations regarding enrollment and the announcement of additional clinical data, and the clinical activity and safety and tolerability of the CYAD-02 and CYAD-101 programs. Forward-looking statements may involve known and unknown risks and uncertainties which might cause actual results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. Such risk and uncertainty can be found in Celyad Oncology’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in the latest Annual Report on Form 20-F filed with the SEC and subsequent filings and reports by Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and Celyad Oncology’s actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220131005002/en/

Investor and Media Contacts:



Sara Zelkovic

Communications & Investor Relations Director

Celyad Oncology

investors@celyad.com



Daniel Ferry

Managing Director

LifeSci Advisors, LLC

daniel@lifesciadvisors.com

Source: Celyad Oncology SA

FAQ

When is Celyad Oncology's presentation at the SVB Leerink Global Healthcare Conference?

Celyad Oncology's presentation is scheduled for February 18, 2022, at 8 a.m. ET.

Who will present at the SVB Leerink Global Healthcare Conference for Celyad?

CEO Filippo Petti will present for Celyad Oncology.

What is the focus of Celyad Oncology's business?

Celyad Oncology focuses on developing CAR T therapies for cancer.

What financial support has Celyad Oncology received?

Celyad Oncology has received funding from the Walloon Region of Belgium for its CAR T programs.

What types of CAR T therapies is Celyad developing?

Celyad is developing both allogeneic and autologous CAR T cell therapies.